SCHEMBL5567323

SCHEMBL5567323

CC(C#N)(c1ccc(Cl)c(C(F)(F)F)c1)c1c(Cl)cc(-n2nc(C#N)c(=O)[nH]c2=O)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 14/20 0.47
THRB P10828 14/20 0.47
CYP2C8 P10632 1/20 0.43
CYP2C9 P11712 1/20 0.43
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
S1PR4 O95977 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSP90AA1 P07900 1/20 0.40
MAPT P10636 1/20 0.40
S1PR1 P21453 1/20 0.40
MAPK1 P28482 1/20 0.40
AGTR1 P30556 1/20 0.40
OPRK1 P41145 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ATM Q13315 1/20 0.36
NOTUM Q6P988 1/20 0.34
KMT2A Q03164 1/20 0.34
CTSK P43235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10672779 0.90 THRA (0.44) THRATHRBCYP2C8CYP2C9KDM4E
SCHEMBL5566123 0.86 ATM (0.45) THRATHRBKDM4EMAPTHTT
SCHEMBL10421417 0.86 THRA (0.51) THRATHRBCYP2C8CYP2C9KDM4E
SCHEMBL5561375 0.83 MEN1 (0.46) THRATHRBALDH1A1KMT2A
SCHEMBL6490396 0.83 ATM (0.41) THRATHRBATMNOTUMKMT2A
SCHEMBL10420817 0.81 THRA (0.48) THRATHRBCYP2C8CYP2C9KDM4E
SCHEMBL10421459 0.79 THRA (0.42) THRATHRBCYP2C8CYP2C9KDM4E
SCHEMBL10419922 0.77 THRA (0.46) THRATHRBCYP2C8CYP2C9KDM4E
SCHEMBL10420162 0.77 THRA (0.47) THRATHRBCYP2C8CYP2C9KDM4E
SCHEMBL10421411 0.77 ATM (0.46) THRATHRBKDM4EMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1000040-B1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 EP disclosed
US-6951857-B2 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma FREYNE EDDY JEAN EDGARD 2005-10-04 US disclosed
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2005-04-28 US disclosed
US-6867207-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-15 US disclosed
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2004-08-26 US disclosed
US-6743792-B2 ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2004-06-01 US disclosed
US-20030220331-A1 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma FREYNE EDDY JEAN EDGARD (BE) 2003-11-27 US disclosed
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives LACRAMPE JEAN FERNAND ARMAND (FR) 2002-06-13 US disclosed
US-20020042416-A1 Antiinflammatory agents FREYNE EDDY JEAN EDGARD (BE) 2002-04-11 US disclosed
EP-1003729-A1 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-31 EP disclosed
EP-1000040-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-17 EP disclosed
WO-1999002505-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed
WO-1999002504-A1 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs IL6ST, CXCR5, ALOX5 THRA 637/4885THRB 481/4885CYP2C8 378/4885
US-20020042416-A1 Antiinflammatory agents CCR1, CCR6, FPR1 THRA 3863/4885THRB 3972/4885CYP2C8 567/4885
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs CXCR5, HCAR3, IL6ST THRA 644/4885THRB 474/4885CYP2C8 267/4885
US-20030220331-A1 Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma IL6, CCR1, CCR6 THRA 3013/4885THRB 3128/4885CYP2C8 827/4885
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives IL6ST, ALOX5, IL5 THRA 1586/4885THRB 1517/4885CYP2C8 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.